Regressing cutaneous malignant melanoma and vitiligo-like depigmentation

International Journal of Dermatology

Volumn 45, Issue 8, 2006, Pages 952-956

  Arpaia, Nicola ^a,b   Cassano, Nicoletta ^a,b   Vena, Gino A ^a,b  

^a UNIVERSITY OF BARI   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AXILLARY LYMPH NODE; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEPIGMENTATION; DISEASE ASSOCIATION; EPILUMINESCENCE MICROSCOPY; FEMALE; HISTOPATHOLOGY; HUMAN; HYPOMELANOSIS; LEUKODERMA; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHADENOPATHY; MELANOCYTIC NEVUS; MELANOMA; PHYSICAL EXAMINATION; REVIEW; SKIN CYST; TREATMENT OUTCOME; VITILIGO;

AGED; FEMALE; HUMANS; HYPOPIGMENTATION; LYMPHATIC DISEASES; MELANOMA; NEOPLASM REGRESSION, SPONTANEOUS; SKIN NEOPLASMS; VITILIGO;

EID: 33746596594     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2004.02468.x     Document Type: Review

References (51)

1. Ortonne JP, Gauthier Y, Guillet G, et al. Depigmentation cutanee associee au melanome malin. Ann Dermatol Venereol 1978; 105: 1043-1052.
2. Aisenbrey S, Luke C, Ayertey HD, et al. Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: An 11-year follow-up. Graefes Arch Clin Exp Ophthalmol 2003; 241: 996-999.
3. Cui J, Bystryn JC. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch Dermatol 1995; 131: 314-318.
4. Yee C, Thompson JA, Roche P, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo. J Exp Med 2000; 192: 1637-1644.
5. Le Gal FA, Avril MF, Bosq J, et al. Direct evidence to support the role of antigen-specific CD8 (+) T cells in melanoma-associated vitiligo. J Invest Dermatol 2001; 117: 1464-1470.
6. Hornung MO, Krementz ET. Specific tissue and tumor responses of chimpanzees following immunization against human melanoma. Surgery 1974; 75: 477-486.
7. Cui J, Chen D, Misfeldt ML, et al. Antimelanoma antibodies in swine with spontaneously regressing melanoma. Pigment Cell Res 1995; 8: 60-63.
8. Nordlund JJ, Kirkwood JM, Forget BM, et al. Vitiligo in patients with metastatic melanoma: A good prognostic sign. J Am Acad Dermatol 1983; 9: 689-696.
9. Bystryn JC, Rigel D, Friedman RJ, et al. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987; 123: 1053-1055.
10. Duhra P, Ilchyshyn A. Prolonged survival in metastatic malignant melanoma associated with vitiligo. Clin Exp Dermatol 1991; 16: 303-305.
11. Richards JM, Mehta N, Ramming K, et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992; 10: 1338-1343.
12. Scheibenbogen C, Hunstein W, Keilholz U. Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients. Eur J Cancer 1994; 30A: 1209-1211.
13. Le Gal FA, Paul C, Chemaly P, et al. More on cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol 1996; 35: 650-651.
14. Rosenberg SA, White DE. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 1996; 19: 81-84.
15. Buendia-Eisman A, Serrano-Ortega S, Ortega Del Olmo R. Vitiligo-like lesions in patients with melanoma treated with immune therapy. Eur J Dermatol 1997; 7: 522-524.
16. Okamoto T, Irie RF, Fujii S, et al. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 1998; 111: 1034-1039.
17. Schreiber S, Kampgen E, Wagner E, et al. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study. Hum Gene Ther 1999; 10: 983-993.
18. Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19: 3477-3482.
19. 34 (+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61: 6451-6458.
20. Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003; 21: 4016-4026.
21. Rodriguez-Cuevas S, Lopez-Chavira A, Zepeda del Rio G, et al. Prognostic significance of cutaneous depigmentation in Mexican patients with malignant melanoma. Arch Med Res 1998; 29: 155-158.
22. Wankowicz-Kalinska A, Le Poole C, van den Wijngaard R, et al. Melanocyte-specific immune response in melanoma and vitiligo: Two faces of the same coin? Pigment Cell Res 2003; 16: 254-260.
23. Engelhard VH, Bullock TN, Colella TA, et al. Antigens derived from melanocyte differentiation proteins: Self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev 2002; 188: 136-146.
24. Nordlund JJ. The epidemiology and genetics of vitiligo. Clin Dermatol 1997; 15: 875-878.
25. Burdick KH, Hawk WA. Vitiligo in a case of vaccinia virus-treated melanoma. Cancer 1964; 17: 708-712.
26. Nirankari MS, Khanna KK, Mathur RP. Uveal malignant melanoma with leucoderma. J All India Ophthalmol Soc 1968; 16: 63-66.
27. Frenk E. Depigmentations vitiligineuses chez des patients atteints de melanomes malins. Dermatologica 1969; 139: 84-91.
28. Balabanov K, Andreev VC, Tchernozemski I. Malignant melanoma and vitiligo. Dermatologica 1969; 139: 211-219.
29. Milton GW, McCarthy WH, Carlon A. Malignant melanoma and vitiligo. Australas J Dermatol 1971; 12: 131-142.
30. Klaus SN, Lerner AB, Bystryn JC. Malignant melanoma and vitiligo. J Invest Dermatol 1971; 73: 491-494.
31. Donaldson RC, Canaan SA Jr, McLean RB, et al. Uveitis and vitiligo associated with BCG treatment for malignant melanoma. Surgery 1974; 76: 771-778.
32. Happle R, Schotola I, Macher E. Spontanregression und Leukoderm beim malignen Melanom. Hautarzt 1975; 26: 120-123.
33. Fodor J, Bodrogi I. Vitiligo and malignant melanoma. Neoplasma 1975; 22: 445-448.
34. Gregor RT. Vitiligo and malignant melanoma: A significant association? S Afr Med J 1976; 50: 1447-1449.
35. Perrot H, Ortonne JP, Schmitt D. Vitiliginous achromia with malignant melanoma. Tyrosinase activity and ultrastructural study of achromic and normal skin. Arch Dermatol Res 1977; 257: 247-253.
36. Ortonne JP, Perrot H. Giant melanin granules in vitiliginous achromia with malignant melanoma. Acta Derm Venereol 1978; 58: 475-480.
37. Cohen Y, Haim S, Bartal A, et al. Vitiligo associated with BCG-methanol extraction residue in malignant melanoma. Report of a case. Dermatologica 1979; 158: 8-12.
38. Forrest JB, Forrest HJ. Case report: Malignant melanoma arising during drug therapy for vitiligo. J Surg Oncol 1980; 13: 337-340.
39. Albert DM, Todes-Taylor N, Wagoner M, et al. Vitiligo or halo nevi occurring in two patients with choroidal melanoma. Arch Dermatol 1982; 118: 34-36.
40. Koh HK, Sober AJ, Nakagawa H, et al. Malignant melanoma and vitiligo-like leukoderma: An electron microscopic study. J Am Acad Dermatol 1983; 9: 696-708.
41. Barriere H, Litoux P, Le Lay M, et al. Achromies cutanees et melanome malin. Ann Dermatol Venereol 1984; 111: 991-996.
42. Lerner AB, Kirkwood JM. Vitiligo and melanoma: Can genetically abnormal melanocytes result in both vitiligo and melanoma within a single family? J Am Acad Dermatol 1984; 11: 696-701.
43. Chang MA, Fournier G, Koh HK, et al. Ocular abnormalities associated with cutaneous melanoma and vitiligolike leukoderma. Graefes Arch Clin Exp Ophthalmol 1986; 224: 529-535.
44. Alabi GO, Falope ZF, Lekwauwa UG. Coexisting malignant melanoma and vitiligo in a Nigerian. West Afr J Med 1991; 10: 443-446.
45. Schallreuter KU, Levenig C, Berger J. Vitiligo and cutaneous melanoma. A case study. Dermatologica 1991; 183: 239-245.
46. Cavallari V, Cannavò SP, Ussia AF, et al. Vitiligo associated with metastatic malignant melanoma. Int J Dermatol 1996; 35: 738-740.
47. Epstein WL, Sagebeil R, Spitler L, et al. Halo nevi and melanoma. JAMA 1973; 225: 373-377.
48. Lindelof B, Hedblad MA, Sigurgeirsson B. On the association between vitiligo and malignant melanoma. Acta Derm Venereol 1998; 78: 483-484.
49. Argenziano G, Soyer HP, De Giorgi V, et al. Dermoscopy: A Tutorial. Milan, Italy: Edra Medical Publishing & New Media, 2000.
50. Carli P, De Giorgi V, Massi D, et al. The role of pattern analysis and the ABCD rule of dermoscopy in the detection of histological atypia in melanocytic naevi. Br J Dermatol 2000; 143: 290-297.
51. Massi D, De Giorgi V, Carli P, et al. Diagnostic significance of the blue hue in dermoscopy of melanocytic lesions: A dermoscopic-pathologic study. Dermatol Surg 2003; 29: 965-967.